ERAL1 and benign neoplasm: Furthermore, the HERA trial indicates that for lymph node-negative (N0) patients who receive anti HER2-targeted therapy, there was no significant difference in the rate of locoregional recurrence following post-mastectomy radiation therapy (PMRT) (P-value = 0.96).